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Integrated care of patients with atrial
ﬁbrillation: the 2016 ESC atrial
ﬁbrillation guidelines
Paulus Kirchhof1,2,3,4
Atrial ﬁbrillation (AF) is one of the evolv-
ing epidemics in cardiovascular medicine.
AF is projected to develop in 25% of cur-
rently 40-year-old adults,1 2 provokes
many, often severe strokes, is associated
with increased mortality and often leads to
heart failure or sudden death even in well-
anticoagulated patients.3 4 The last few
years have seen the development of new
approaches to detect and treat patients
with AF, from ECG screening to surgical
procedures to prevent recurrent AF. While
these improvements provide tools to
improve outcomes and quality of life in
affected patients, they often need multidis-
ciplinary input into patient management. It
therefore seems timely that the European
Society of Cardiology (ESC) has issued
new AF guidelines in August 2016.5
GOOD MANAGEMENT OF PATIENTS
WITH AF REQUIRES A TEAM EFFORT
Reﬂecting the need for multidisciplinary
input, the 2016 ESC AF guidelines task
force consisted of cardiologists with differ-
ent degrees of sub-specialisation, cardiac
surgeons, a stroke neurologist and a spe-
cialist nurse, nominated by the ESC and its
constituent bodies including the European
Heart Rhythm Association, the European
Association of Cardio-Thoracic Surgeons
and the European Stroke Organization. All
recommendations were discussed and
voted upon in a predeﬁned process, accept-
ing only recommendations supported by at
least 75% of the Task Force members after
a structured consultation. Thirty-three
general reviewers reviewed the entire
guideline in three iterations, while 49 add-
itional reviewers nominated by the ESC
National Societies focusing on the class I
and III recommendations provided further
valuable comments.5
SCREENING FOR AF
ECG screening can help detect asymptom-
atic AF, allowing timely initiation of
therapy, especially oral anticoagulation.
This has the potential to prevent compli-
cations of AF, especially ischaemic strokes.
The ESC guidelines recommend oppor-
tunistic ECG screening whenever a person
aged 65 years or older is seen by a health-
care professional.6 In addition, and
beyond prior guidelines, systematic ECG
monitoring for at least 72 hours is recom-
mended for patients with stroke or transi-
ent ischaemic attack (TIA),7 8 with a
suggestion that even longer ECG monitor-
ing should be considered, especially when
a cardioembolic origin of the stroke is sus-
pected.9 10 More data are needed to
inform the best approach to systematic
screening of high-risk population using
patient-operated or ‘smart’ devices, with
promising initial results in populations
aged 75 and above.11
INTEGRATED AF CARE ALIGNED WITH
PATIENT NEEDS
Once AF is diagnosed, patients should be
offered treatment in ﬁve domains:
1. acute haemodynamic stabilisation in
haemodynamically unstable patients
(eg, by cardioversion, rate control, cir-
culatory support, etc);
2. detection and treatment of concomi-
tant cardiovascular conditions;
3. stroke risk assessment and oral antic-
oagulation in patients with AF at risk
for stroke;
4. rate control therapy in patients with
elevated ventricular rates during AF;
5. rhythm control therapy in patients
who remain symptomatic on rate
control therapy.
Optimal management of patients with
AF requires input from different medical
specialties and professions. Integrated care
models should be considered for all
patients with AF, supporting shared
decision-making and empowering patients
to own their care, providing support
where needed and giving access to all
specialist treatment options when appro-
priate (ﬁgure 1).12 Such care models will
require close cooperation between AF spe-
cialists, stroke physicians, AF surgeons,
general cardiologists and general practi-
tioners. In addition, continued high-
quality care may need further support
from allied healthcare professionals,
patients, and family members.
INITIAL ASSESSMENT OF PATIENTS
WITH AF
To detect concomitant cardiovascular dis-
eases, an echocardiogram and a careful
analysis of the ECG should be performed
in addition to a complete history and
physical examination (box 1). This infor-
mation will often allow us to decide on
the need for oral anticoagulation. It will
also give a ﬁrst guide on the need to
adapt/initiate rate control therapy, and
provide a ﬁrst idea whether rhythm
control therapy is useful.
ANTICOAGULATION THERAPY IN AF:
AIMING FOR SAFE AND EFFECTIVE
LONG-TERM THERAPY
Many patients with AF are now
adequately initiated on oral anticoagula-
tion therapy based on the CHA2DS2VASc
stroke risk factors that were included in
the 2010 ESC AF guidelines.13 14 This
established system continues to be recom-
mended: patients with two of the
CHA2DS2VASc stroke risk factors congest-
ive heart failure, hypertension, diabetes or
vascular disease, as well as survivors of a
stroke or TIA and those aged 75 or more,
should receive oral anticoagulation.
Patients without any of these stroke risk
factors are at low stroke risk and do not
need antithrombotic therapy. In patients
with one of the CHA2DS2VASc factors,
stroke risk varies,15 and female sex does
not alter stroke risk in these patients (web
addenda Table 1 in Ref. 5,).15 16
Consequently, anticoagulation should be
considered in patients with AF and one
additional stroke risk factor of either sex,
weighing the likely beneﬁt of anticoagula-
tion and the risk of bleeding. In selected
patients, biomarkers may be useful to
reﬁne stroke risk.17
CHOICE OF ANTICOAGULANT
Oral anticoagulation to prevent strokes in
patients with AF can be achieved with
vitamin K antagonists or non-vitamin-K-
antagonist oral anticoagulants (NOACs).
Patients with mechanical heart valves and
those with moderate or severe mitral sten-
osis should be treated with vitamin K
antagonists. Considering their superior
safety compared with warfarin (10%
lower mortality, approximately 50% lower
risk of intracranial haemorrhage or haem-
orrhagic stroke18 19), patients who are eli-
gible for therapy with the NOACs
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apixaban, dabigatran, edoxaban or rivar-
oxaban (in alphabetical order) should
preferentially be treated with a NOAC.
ENSURING SAFE AND CONTINUED
ORAL ANTICOAGULATION THERAPY
While oral anticoagulation is increasingly
used in patients with AF at risk of stroke,
many patients with AF are taken off
anticoagulants in the ﬁrst year after initi-
ation. Therefore, a large portion of the
guidelines is dedicated to the safe con-
tinuation of oral anticoagulation therapy
in patients with AF. The guidelines
provide a list of four modiﬁable bleeding
risk factors (box 2). Minimising these
factors is recommended as a simple way
to reduce the risk of major bleeding in
anticoagulated AF patients. Furthermore,
there are recommendations and ﬂow
charts to
1. inform the management of patients
with a bleed, including the use of
reversal agents;
2. suggest the reinitiation of oral anticoa-
gulation after an ischaemic stroke;
3. support the difﬁcult decisions that
need to be taken in patients who suf-
fered an intracranial bleed on oral
anticoagulation.
A SIMPLIFIED APPROACH TO RHYTHM
CONTROL THERAPY IN PATIENTS
WITH SYMPTOMATIC AF
There are no major changes to the recom-
mendations for rate control therapy.
Rhythm control therapy continues to be
indicated to improve AF-related symp-
toms, usually on top of management of
concomitant conditions, stroke prevention
therapy and rate control therapy. The
indications for antiarrhythmic drug
therapy have not changed. The new
guidelines provide more detailed informa-
tion about the ECG changes that are
warning signs for proarrhythmia. Catheter
ablation targeting isolation of the pulmon-
ary veins20–22 is a valid rhythm control
therapy option and should be discussed
with patients in need for rhythm control
therapy. When AF recurs and further
rhythm control therapy is warranted,
‘hybrid therapy’ (eg, combining antiar-
rhythmic drugs with catheter ablation)
will often help: in patients who need
further rhythm control therapy despite
antiarrhythmic drug therapy, catheter
ablation is often effective. Patients who
Figure 1 The ﬁve domains of
integrated atrial ﬁbrillation (AF) care.
All patients with AF should receive
care directed at these ﬁve domains. LV,
left ventricular. Reproduced with
permission from Ref. 5.
Box 1 Clinical information informing atrial ﬁbrillation (AF) management
▸ Age
▸ Living conditions, personal autonomy (or frailty) and ability to care for oneself
▸ Blood pressure, history of hypertension and antihypertensive therapy
▸ Diagnosed diabetes or current therapy with antidiabetic substances
▸ Prior stroke or transient ischaemic attack
▸ Breathlessness upon exertion, New York Heart Association class (eg, walking distance
without breathlessness, ability to climb more than three ﬂights of stairs without a
pause), history of heart failure, left ventricular dysfunction, current treatment with
heart failure medication
▸ Other vascular disease, eg, carotid artery or peripheral artery disease
▸ Cardiac murmur, history of valvular heart disease or signs of valvular heart disease
on echocardiogram
▸ Prior cardiovascular operations or interventions
▸ Exertional chest pain, prior myocardial infarction, percutaneous coronary intervention
or bypass surgery, Canadian Cardiovascular Society class
▸ Current anticoagulant or antiplatelet therapy, history of anticoagulation therapy
including complications or reasons for interruption
▸ Heart rate on ECG and on palpation, current rate control therapy, prior rate control
therapy (digitalis preparations, verapamil/diltiazem, β-blockers)
▸ Symptoms when in AF, frequency of episodes, modiﬁed European Heart Rhythm
Association score
▸ Current antiarrhythmic drug therapy, prior antiarrhythmic drug therapy, cardioversion,
catheter ablation or surgical AF procedures
▸ Other relevant ﬁndings on ECG or echocardiogram
▸ Other current medications
Box 2 Modiﬁable bleeding risk
factors in anticoagulated atrial
ﬁbrillation patients
▸ Hypertension (especially when systolic
blood pressure is >160 mm Hg)
▸ Labile International Normalized Ratio
(INR) or time in therapeutic range
<60% in patients on vitamin
K antagonists
▸ Medication predisposing to bleeding,
such as antiplatelet drugs and
non-steroidal anti-inﬂammatory drugs
▸ Excess alcohol (≥8 drinks/week)
▸ Reproduced with permission from Ref.5
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need a third attempt to rhythm control
therapy should be discussed with an AF
Heart Team including consideration of AF
surgery.
The new guidelines suggest a very
similar approach to rhythm control in
patients with paroxysmal (self-
terminating) and persistent AF: the ﬂow
charts are not different by AF pattern.
This simpliﬁcation is supported by two
observations: the time in sinus rhythm as
assessed by an implanted device is not
that different between patients who are
clinically classiﬁed as ‘paroxysmal’ or ‘per-
sistent’ AF.23 Furthermore, the available
controlled trials suggest that catheter abla-
tion is more effective than antiarrhythmic
drugs and cardioversion in patients with
persistent AF,24 similar to paroxysmal AF.
AF HEART TEAMS
Integrated AF care has the potential to
provide continued care in the community
while maintaining specialist input for
most patients with AF (ﬁgure 1). Difﬁcult
situations, for example, arising in patients
who develop a stroke or an intracerebral
bleed on anticoagulation, or in patients
who need more intensive rhythm control
therapy despite initially successful ablation
and antiarrhythmic drug therapy, should
be discussed in AF Heart Teams. Such
teams have already formed, for example,
for decisions regarding left atrial append-
age occluders, but there seems to be a
need to form more local AF Heart
Teams.25
OUTLOOK
The 2016 ESC guidelines for AF summar-
ise the current evidence-based therapy for
AF in a practical way. Implementing this
evidence-based management successfully,
probably using integrated AF care models
supported by digital tools such as the AF
section in the ESC pocket guidelines app,
has the potential to substantially improve
outcomes in patients with AF. Even on
optimal therapy, premature cardiovascular
deaths, hospitalisations for cardiovascular
problems and diminished autonomy are
common. Hence, there is a clear need for
further research into the causes of AF,
into better ways to prevent AF, the role of
rhythm and rate control therapy for
AF-related outcomes, and into improved
treatment of patients with AF.
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